Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  OTC Bulletin Board  >  Windtree Therapeutics Inc    WINT

WINDTREE THERAPEUTICS INC

(WINT)
SummaryNewsCalendarCompany 
News SummaryMost relevantAll newsOfficial PublicationsSector news

WINDTREE THERAPEUTICS INC /DE/ : Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits (form 8-K)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/14/2019 | 04:18pm EDT

Item 2.02. Results of Operations and Financial Condition.

On August 14, 2019, Windtree Therapeutics, Inc. (the "Company") issued a press release highlighting the results of operations for the quarter ended June 30, 2019 and providing key financial and business updates. The press release is attached as Exhibit 99.1 hereto.

In accordance with General Instruction B.2 of Form 8-K, the information in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 hereto relating to the announcement of the results of operations for the quarter ended June 30, 2019 and all other matters except for those discussed under Item 8.01 below shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in any such filings.


Item 8.01. Other Events.


The press release referred to in Item 2.02 also provides certain program updates relating to the Company's lead programs - istaroxime for acute heart failure and AEROSURF® for respiratory distress syndrome (RDS) in premature infants. In addition, the Company reports that, before any additional financings, the Company anticipates that it will have sufficient cash, cash equivalents and available-for-sale marketable securities to fund its development activities, business operations and debt service through October 2019.

Subject to the note relating to the press release contained in Item 2.02 of this Current Report on Form 8-K, the press release is attached as Exhibit 99.1 hereto.

Item 9.01 Financial Statements and Exhibits.



(d)   Exhibits.


99.1 Press Release of Windtree Therapeutics, Inc., dated August 14, 2019.

Cautionary Note Regarding Forward-looking Statements:

To the extent that statements in this Current Report on Form 8-K are not strictly historical, including statements as to business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's product development, cash flows, future revenues, the timing of planned clinical trials or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this Current Report are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Such risks and others are further described in the Company's filings with the Securities and Exchange Commission including the most recent reports on Forms 10-K, 10-Q and 8-K, and any amendments thereto. Any forward-looking statement made by the Company in this Current Report on Form 8-K is based only on information currently available to the Company and speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on WINDTREE THERAPEUTICS INC
08/14WINDTREE THERAPEUTICS : DE/ Management's Discussion and Analysis of Financial Co..
AQ
08/14WINDTREE THERAPEUTICS INC /DE/ : Results of Operations and Financial Condition, ..
AQ
06/20WINDTREE THERAPEUTICS : to Host Research and Development Day in New York City on..
AQ
06/05WINDTREE THERAPEUTICS : and Eleison Announce Initial Results of Delivering Inhal..
AQ
05/31WINDTREE THERAPEUTICS INC /DE/ : Other Events, Financial Statements and Exhibits..
AQ
05/31WINDTREE THERAPEUTICS : Istaroxime Phase 2b Study Results Presented in Late Brea..
AQ
05/31WINDTREE THERAPEUTICS : Istaroxime Phase 2b Study Results Presented in Late Brea..
AQ
05/20WINDTREE THERAPEUTICS : DE/ Management's Discussion and Analysis of Financial Co..
AQ
04/30WINDTREE THERAPEUTICS INC /DE/ : Change in Directors or Principal Officers, Othe..
AQ
04/23WINDTREE THERAPEUTICS : De/ - 10-k/a - management's discussion and analysis of f..
AQ
More news